Fibrosis is a chronic disease characterized by excessive extracellular matrix production, which leads to disruption of organ function. Fibroblasts are key effector cells of this process, responding chiefly to the pleiotropic cytokine transforming growth factor-β1 (TGF-β1), which promotes fibroblast to myofibroblast differentiation. We found that extracellular nutrient availability profoundly influenced the TGF-β1 transcriptome of primary human lung fibroblasts and that biosynthesis of amino acids emerged as a top enriched TGF-β1 transcriptional module.
View Article and Find Full Text PDFObjectives: A previous pilot study showed that pravastatin supplementation improved pregnancy outcomes in women with obstetric antiphospholipid syndrome (OAPS) that developed placental insufficiency despite standard of care treatment low molecular weight heparin plus low dose aspirin (LMWH + LDA). In this study we investigated the mechanism behind the beneficial effects of the triple therapy LMWH + LDA + pravastatin in improving uteroplacental vascular function and reducing pregnancy complications in OAPS. We hypothesized that nitric oxide (NO) is involved in the vasculoprotective effects of the triple therapy.
View Article and Find Full Text PDFThe differentiation of fibroblasts into a transient population of highly activated, extracellular matrix (ECM)-producing myofibroblasts at sites of tissue injury is critical for normal tissue repair. Excessive myofibroblast accumulation and persistence, often as a result of a failure to undergo apoptosis when tissue repair is complete, lead to pathological fibrosis and are also features of the stromal response in cancer. Myofibroblast differentiation is accompanied by changes in cellular metabolism, including increased glycolysis, to meet the biosynthetic demands of enhanced ECM production.
View Article and Find Full Text PDFThe development and commercialization of Photovoltaic (PV) cells with good cost-efficiency trade-off not using critical raw materials (CRMs) is one of the strategies chosen by the European Community (EC) to address the Energy Roadmap 2050. In this context Cu2ZnSnS4 (CZTS) solar cells are attracting a major interest since they have the potential to combine low price with relatively high conversion efficiencies. Although a ≈9% lab scale efficiency has already been reported for CZTS this technology is still far from being competitive in terms of cost per peak-power (€/Wp) with other common materials.
View Article and Find Full Text PDF